Cadent Capital Advisors’s AstraZeneca AZN Stock Holding History

Cadent Capital Advisors’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.91M	Buy	+10,077	New	+$1.9M	0.39%	72

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Cadent Capital Advisors's AZN Position: Q2 2026 in Review

Cadent Capital Advisors opened a new position in AstraZeneca (AZN) in Q2 2026: 10,077 shares worth $1.91M. The stake represents 0.39% of the portfolio and ranks #72 among its holdings.

1,498 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Cadent Capital Advisors held 10,077 shares of AstraZeneca worth $1.91M as of Q2 2026.
AstraZeneca was a new Cadent Capital Advisors position in Q2 2026.
AstraZeneca made up 0.39% of Cadent Capital Advisors's portfolio in Q2 2026, its #72 holding.
1,498 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Cadent Capital Advisors's 13F filing for Q2 2026, filed 14 Jul 2026.